Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Risk of statin-induced rhabdomyolysis in patients with hepatic impairment.

Kolhe N, Lewis J, McCulloch TA.

BMJ Case Rep. 2014 Sep 11;2014. pii: bcr2014204013. doi: 10.1136/bcr-2014-204013.

PMID:
25213784
2.

Effect of statin use on outcome of symptomatic cholelithiasis: a case-control study.

Pulkkinen J, Eskelinen M, Kiviniemi V, Kotilainen T, Pöyhönen M, Kilpeläinen L, Käkelä P, Kastarinen H, Paajanen H.

BMC Gastroenterol. 2014 Jul 3;14:119. doi: 10.1186/1471-230X-14-119.

3.

Declining cholecystectomy rate during the era of statin use in Finland: a population-based cohort study between 1995 and 2009.

Suuronen S, Niskanen L, Paajanen P, Paajanen H.

Scand J Surg. 2013;102(3):158-63. doi: 10.1177/1457496913492463.

PMID:
23963029
4.

Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.

Wang HH, Portincasa P, de Bari O, Liu KJ, Garruti G, Neuschwander-Tetri BA, Wang DQ.

Eur J Clin Invest. 2013 Apr;43(4):413-26. doi: 10.1111/eci.12058. Epub 2013 Feb 19. Review.

5.

Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease.

Cariati A, Piromalli E.

Expert Opin Pharmacother. 2012 Jun;13(9):1223-7. doi: 10.1517/14656566.2012.685161. Review.

PMID:
22607008
6.

Statin use and the risk of gallstone disease: a population-based case-control study.

Chiu HF, Chen CC, Kuo HW, Lee IM, Wu TN, Yang CY.

Expert Opin Drug Saf. 2012 May;11(3):369-74. doi: 10.1517/14740338.2012.653560. Epub 2012 Jan 14.

PMID:
22243480
7.

Lipid lowering drugs and gallstones: a therapeutic option?

Lioudaki E, Ganotakis ES, Mikhailidis DP.

Curr Pharm Des. 2011 Nov;17(33):3622-31. Review.

PMID:
22074432
8.

Long-term use of fenofibrate is associated with increased prevalence of gallstone disease among patients undergoing maintenance hemodialysis.

Liang CC, Wang IK, Kuo HL, Yeh HC, Lin HH, Liu YL, Hsu WM, Huang CC, Chang CT.

Ren Fail. 2011;33(5):489-93. doi: 10.3109/0886022X.2011.577545.

PMID:
21574895
9.

Targets for current pharmacologic therapy in cholesterol gallstone disease.

Di Ciaula A, Wang DQ, Wang HH, Bonfrate L, Portincasa P.

Gastroenterol Clin North Am. 2010 Jun;39(2):245-64, viii-ix. doi: 10.1016/j.gtc.2010.02.005. Review.

10.

Use of statins and gallstone risk.

Hsu CS, Kao JH.

JAMA. 2010 Mar 24;303(12):1146; author reply 1147. doi: 10.1001/jama.2010.320. No abstract available.

PMID:
20332396
11.

Use of statins and gallstone risk.

Fujita T.

JAMA. 2010 Mar 24;303(12):1146-7; author reply 1147. doi: 10.1001/jama.2010.321. No abstract available.

PMID:
20332395
12.

Statin use and risk of gallstone disease followed by cholecystectomy.

Bodmer M, Brauchli YB, Krähenbühl S, Jick SS, Meier CR.

JAMA. 2009 Nov 11;302(18):2001-7. doi: 10.1001/jama.2009.1601.

PMID:
19903921
13.

Statin use and the risk of cholecystectomy in women.

Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL.

Gastroenterology. 2009 May;136(5):1593-600. doi: 10.1053/j.gastro.2009.01.042. Epub 2009 Jan 24.

14.

The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model.

Davis KG, Wertin TM, Schriver JP.

Obes Surg. 2003 Dec;13(6):865-8.

PMID:
14738672
15.

Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs.

Abedin MZ, Narins SC, Park EH, Smith PR, Kirkwood KS.

Dig Dis Sci. 2002 Oct;47(10):2192-210.

PMID:
12395892
16.

Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism.

Hillebrant CG, Nyberg B, Gustafsson U, Sahlin S, Björkhem I, Rudling M, Einarsson C.

Eur J Clin Invest. 2002 Jul;32(7):528-34.

PMID:
12153554
17.

Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index.

Porsch-Ozçürümez M, Hardt PD, Schnell-Kretschmer H, von Bergmann K, Darui C, Nonhoff J, Abletshauser C, Klör HU.

Eur J Clin Pharmacol. 2001 Mar;56(12):873-9.

PMID:
11317474
18.

Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones.

Smith JL, Roach PD, Wittenberg LN, Riottot M, Pillay SP, Nestel PJ, Nathanson LK.

J Gastroenterol Hepatol. 2000 Aug;15(8):871-9.

PMID:
11022827
19.

Deoxycholic acid treatment in patients with cholesterol gallstones: failure to detect a suppression of cholesterol 7alpha-hydroxylase activity.

Hillebrant C, Nyberg B, Angelin B, Axelson M, Björkhem I, Rudling M, Einarsson C.

J Intern Med. 1999 Oct;246(4):399-407.

20.

The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease.

Smit JW, van Erpecum KJ, Renooij W, Stolk MF, Edgar P, Doornewaard H, Vanberge-Henegouwen GP.

Hepatology. 1995 Jun;21(6):1523-9.

PMID:
7768495
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk